Highlights for the three months ended
- Net sales of
$386.8 million , an increase of$22.9 million , or 6% - Net income of
$29.5 million , an increase of$3.0 million , or 11% - Diluted income per share of
$0.72 , an increase of$0.07 , or 11% - Adjusted EBITDA of
$64.3 million , an increase of$2.4 million , or 4% - Adjusted net income of
$32.4 million , an increase of$2.5 million , or 9% - Adjusted diluted EPS of
$0.79 , an increase of$0.06 , or 8%
Our fiscal year 2027 Net Sales and Adjusted EBITDA guidance is as follows:
- Net sales of
$1.55 billion to$1.60 billion - Adjusted EBITDA of
$258 million to$268 million - Adjusted net income of
$140 million to$147 million
COMMENTARY
“We are pleased with our start to fiscal 2027,” said
“When we set our fiscal 2027 outlook in August, we took a disciplined approach to virginiamycin sales in
“We generated positive cash flow in the first quarter, and we see a clear opportunity to do more, particularly in managing inventory. Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”
“The first quarter was a solid start to the year. Given the timing of certain costs and the assumptions already built into our outlook, we are maintaining our fiscal 2027 financial guidance.”
QUARTERLY RESULTS
Net sales
Net sales of
Net sales of
Net sales of nutritional specialty products decreased
Net sales of vaccines decreased
Mineral Nutrition
Net sales of?$73.6 million for the three months ended
Performance Products
Net sales of
Gross profit
Gross profit of
Excluding the items discussed above,
Selling, general and administrative expenses
Selling, general and administrative expenses (“SG&A”) of
Animal Health SG&A, excluding the non-recurring
Interest expense, net
Interest expense, net of
Foreign currency (gains) losses, net
Foreign currency gains, net for the three months ended
Provision for income taxes
The provision for income taxes was
The effective income tax rate in the current year was higher than the federal statutory rate of 21% primarily due to the impact of state and local income taxes and the mix of foreign income, offset by tax credits.
The effective income tax rate in the current period included, among other items, foreign currency gains and certain stock-based compensation, which had lower tax rates. The effective income tax rate in the prior year included, among other items, (i) a
It is reasonably possible we will resolve a foreign tax audit in a future quarter during this fiscal year that may have a favorable impact on our income tax rate. The Company cannot yet estimate the impact of this potential future benefit on its financial statements.
Net income
Net income of
Adjusted EBITDA
Adjusted EBITDA of
Adjusted provision for income taxes
The adjusted provision for income taxes was
Adjusted net income
Adjusted net income of
Adjusted diluted earnings per share
Adjusted diluted earnings per share was
BALANCE SHEET AND CASH FLOWS
- Free cash flow was
$21.7 million for the twelve months endedSeptember 30, 2026 . (Free cash flow equals cash flow from operating activities less capital expenditures.) - 2.9x gross leverage ratio as of
September 30, 2026 $739.6 million total debt$257.4 million Adjusted EBITDA for the twelve months endedSeptember 30, 2026
- Cash and short-term investments of
$83.1 million as ofSeptember 30, 2026
FISCAL YEAR 2027 FINANCIAL GUIDANCE
Our fiscal year 2027 financial guidance is as shown below, with our guidance maintained from the previous quarter. Year-over-year percentages are calculated using the midpoint of the guidance ranges.
- Net sales of
$1.55 billion to$1.60 billion , 4% growth - Net income of
$122 million to$132 million , 27% growth - Diluted EPS of
$2.98 to$3.22 , 27% growth - Adjusted EBITDA of
$258 million to$268 million , 3% growth - Adjusted net income of
$140 million to$147 million , 9% growth - Adjusted diluted EPS of
$3.41 to$3.59 , 9% growth - Adjusted effective income tax rate of ~20%
Guidance for GAAP measures assumes no additional foreign exchange (gains) losses for the year ending
WEBCAST & CONFERENCE CALL DETAILS
Date: | ||
Time: | ||
Location: | ||
+ 1 (833) 461-5787 | ||
International Toll: | 1 (585) 542-9983 | |
Conference ID: | 646434646 |
NOTE: To join this conference call, all participants will be required to provide the Conference ID number.
A replay of the webcast will be archived and made available on Phibro’s website.
DISCLOSURE NOTICES
Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income, adjusted diluted EPS and free cash flow to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.
We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.
Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Consolidated Results of Operations | ||||||||||||
| Three Months | ||||||||||||
| For the Periods Ended | 2026 | 2025 | Change | |||||||||
| (in millions, except per share amounts and percentages) | ||||||||||||
| Net sales | $ | 386.8 | $ | 363.9 | $ | 22.9 | 6 | % | ||||
| Cost of goods sold | 258.2 | 244.1 | 14.1 | 6 | % | |||||||
| Gross profit | 128.5 | 119.8 | 8.8 | 7 | % | |||||||
| Selling, general and administrative expenses | 78.9 | 68.5 | 10.4 | 15 | % | |||||||
| Operating income | 49.6 | 51.3 | (1.6) | (3) | % | |||||||
| Interest expense, net | 11.3 | 12.1 | (0.8) | (6) | % | |||||||
| Foreign currency (gains) losses, net | (0.4) | 2.9 | (3.4) | * | ||||||||
| Income before income taxes | 38.8 | 36.3 | 2.5 | 7 | % | |||||||
| Provision for income taxes | 9.3 | 9.7 | (0.5) | (5) | % | |||||||
| Net income | $ | 29.5 | $ | 26.5 | $ | 3.0 | 11 | % | ||||
| Net income per share | ||||||||||||
| basic | $ | 0.73 | $ | 0.65 | $ | 0.08 | 12 | % | ||||
| diluted | $ | 0.72 | $ | 0.65 | $ | 0.07 | 11 | % | ||||
| Weighted average common shares outstanding | ||||||||||||
| basic | 40.6 | 40.5 | ||||||||||
| diluted | 41.0 | 40.9 | ||||||||||
| Ratio to net sales | ||||||||||||
| Gross profit | 33.2 | % | 32.9 | % | ||||||||
| Selling, general and administrative expenses | 20.4 | % | 18.8 | % | ||||||||
| Operating income | 12.8 | % | 14.1 | % | ||||||||
| Income before income taxes | 10.0 | % | 10.0 | % | ||||||||
| Net income | 7.6 | % | 7.3 | % | ||||||||
| Effective tax rate | 23.9 | % | 26.9 | % | ||||||||
Amounts and percentages may reflect rounding adjustments. | ||||||||||||
* Calculation not meaningful | ||||||||||||
Segment | ||||||||||||
| Three Months | ||||||||||||
| For the Periods Ended | 2026 | 2025 | Change | |||||||||
| (in millions, except percentages) | ||||||||||||
| MFAs and other | $ | 206.5 | $ | 195.2 | $ | 11.3 | 6 | % | ||||
| Nutritional specialties | 47.1 | 48.2 | (1.1) | (2) | % | |||||||
| Vaccines | 39.5 | 40.1 | (0.6) | (2) | % | |||||||
293.0 | 283.5 | 9.6 | 3 | % | ||||||||
| Mineral Nutrition | 73.6 | 63.0 | 10.6 | 17 | % | |||||||
| Performance Products | 20.2 | 17.4 | 2.7 | 16 | % | |||||||
| Total | $ | 386.8 | $ | 363.9 | $ | 22.9 | 6 | % | ||||
| Adjusted EBITDA | ||||||||||||
| $ | 73.9 | $ | 74.9 | $ | (1.0) | (1) | % | |||||
| Mineral Nutrition | 6.2 | 4.5 | 1.6 | 36 | % | |||||||
| Performance Products | 2.8 | 1.6 | 1.2 | 75 | % | |||||||
| Corporate | (18.6) | (19.1) | 0.6 | (3) | % | |||||||
| Total | $ | 64.3 | $ | 61.9 | $ | 2.4 | 4 | % | ||||
| Ratio to segment net sales | ||||||||||||
25.2 | % | 26.4 | % | |||||||||
| Mineral Nutrition | 8.4 | % | 7.2 | % | ||||||||
| Performance Products | 13.9 | % | 9.2 | % | ||||||||
| Corporate(1) | (4.8) | % | (5.3) | % | ||||||||
| Total(1) | 16.6 | % | 17.0 | % | ||||||||
| Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||||||||
| Net income | $ | 29.5 | $ | 26.5 | $ | 3.0 | 11 | % | ||||
| Interest expense, net | 11.3 | 12.1 | (0.8) | (6) | % | |||||||
| Provision for income taxes | 9.3 | 9.7 | (0.5) | (5) | % | |||||||
| Depreciation and amortization | 13.6 | 12.8 | 0.7 | 6 | % | |||||||
| EBITDA | 63.6 | 61.2 | 2.5 | 4 | % | |||||||
| Restructuring charges - SG&A(2) | 0.6 | — | 0.6 | * | ||||||||
| Acquisition-related cost of goods sold | — | 1.1 | (1.1) | * | ||||||||
| Acquisition-related transaction costs | — | 0.3 | (0.3) | * | ||||||||
| Phibro Forward income growth initiatives - SG&A | 0.0 | ** | — | 0.0 | * | |||||||
| Stock-based compensation expense - named executive officer performance awards | 0.4 | 0.2 | 0.2 | * | ||||||||
| Insurance settlement | 0.0 | ** | (3.8) | 3.8 | * | |||||||
| Foreign currency (gains) losses, net | (0.4) | 2.9 | (3.4) | * | ||||||||
| Adjusted EBITDA | $ | 64.3 | $ | 61.9 | $ | 2.4 | 4 | % | ||||
Amounts and percentages may reflect rounding adjustments. | ||||||||||||
* Calculation not meaningful | ||||||||||||
** Amount less than | ||||||||||||
(1) Reflects ratio to total net sales | ||||||||||||
(2) Restructuring charges recorded in SG&A include severance charges and other exit costs related to the planned closure of our manufacturing facility in | ||||||||||||
Adjusted Net Income | ||||||||||||
| Three Months | ||||||||||||
| For the Periods Ended | 2026 | 2025 | Change | |||||||||
| (in millions, except per share amounts and percentages) | ||||||||||||
| Reconciliation of GAAP Net Income to Adjusted Net Income | ||||||||||||
| Net income | $ | 29.5 | $ | 26.5 | $ | 3.0 | 11 | % | ||||
| Acquisition-related depreciation(1) | 1.7 | 1.6 | 0.1 | 8 | % | |||||||
| Acquisition-related intangible amortization(1) | 1.1 | 1.1 | 0.0 | 1 | % | |||||||
| Acquisition-related intangible amortization(2) | 0.6 | 0.6 | 0.0 | 2 | % | |||||||
| Acquisition-related cost of goods sold(1) | — | 1.1 | (1.1) | * | ||||||||
| Acquisition-related transaction costs(2) | — | 0.3 | (0.3) | * | ||||||||
| Restructuring charges - SG&A(2) (3) | 0.6 | — | 0.6 | * | ||||||||
| Insurance proceeds(2) | 0.0 | ** | (3.8) | 3.8 | * | |||||||
| Stock-based compensation expense - named executive officer performance awards | 0.4 | 0.2 | 0.2 | * | ||||||||
| Phibro Forward income growth initiatives - SG&A(2) | 0.0 | ** | — | 0.0 | * | |||||||
| Foreign currency (gains) losses, net(4) | (0.4) | 2.9 | (3.4) | * | ||||||||
| Adjustments to income taxes(5) | (1.2) | (0.7) | 0.5 | (78) | % | |||||||
| Adjusted net income | $ | 32.4 | $ | 29.8 | $ | 2.5 | 9 | % | ||||
| Statement of Operations | ||||||||||||
| Adjusted cost of goods sold(1) | $ | 255.4 | $ | 240.3 | $ | 15.1 | 6 | % | ||||
| Adjusted gross profit | 131.4 | 123.6 | 7.8 | 6 | % | |||||||
| Adjusted selling, general and administrative(2) | 77.2 | 71.3 | 5.9 | 8 | % | |||||||
| Interest expense, net | 11.3 | 12.1 | (0.8) | (6) | % | |||||||
| Adjusted income before income taxes | 42.9 | 40.3 | 2.6 | 6 | % | |||||||
| Adjusted provision for income taxes(5) | 10.5 | 10.4 | 0.1 | 1 | % | |||||||
| Adjusted net income | $ | 32.4 | $ | 29.8 | $ | 2.5 | 9 | % | ||||
| Adjusted net income per share | ||||||||||||
| diluted | $ | 0.79 | $ | 0.73 | $ | 0.06 | 8 | % | ||||
| Weighted average common shares outstanding | ||||||||||||
| diluted | 41.0 | 40.9 | ||||||||||
| Ratio to net sales | ||||||||||||
| Adjusted gross profit | 34.0 | % | 34.0 | % | ||||||||
| Adjusted selling, general and administrative(2) | 20.0 | % | 19.6 | % | ||||||||
| Adjusted income before income taxes | 11.1 | % | 11.1 | % | ||||||||
| Adjusted net income | 8.4 | % | 8.2 | % | ||||||||
| Adjusted effective tax rate | 24.5 | % | 25.9 | % | ||||||||
Amounts and percentages may reflect rounding adjustments. | ||||||||||||
* Calculation not meaningful | ||||||||||||
** Amount less than | ||||||||||||
(1) Adjusted cost of goods sold excludes acquisition-related depreciation associated with the step-up of fair value of the acquired fixed assets, acquisition-related intangible amortization and acquisition-related cost of goods sold. | ||||||||||||
(2) Adjusted selling, general and administrative excludes restructuring-related severance charges and other exit costs related to the planned closure of our manufacturing facility in | ||||||||||||
(3) Restructuring charges recorded in SG&A include severance charges and other exit costs related to the planned closure of our manufacturing facility in | ||||||||||||
(4) Foreign currency (gains) losses, net, are excluded from adjusted net income. | ||||||||||||
(5) Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments. | ||||||||||||
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102016605/en/
Vice President, Finance, Treasurer and Head of Investor Relations
+1-201-329-7300
Or
investor.relations@pahc.com
Source: